Key Points
- Takeda insider Andrew Stewart Plump sold 116,191 shares at an average price of $18.49, generating approximately $2.15 million. The Rule 10b5-1 transaction reduced his direct ownership by 44.41% to 145,465 shares.
- Plump also sold 19,651 shares on August 19 and 165,393 shares on August 10, indicating a series of recent insider sales.
- Takeda recently exceeded earnings expectations, reporting quarterly EPS of $0.95 versus the $0.41 consensus and revenue of $7.50 billion. Analyst sentiment remains a “Moderate Buy,” despite one recent sell rating.
Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Andrew Plump sold 116,191 shares of the business's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the transaction, the insider directly owned 145,465 shares in the company, valued at approximately $2,689,647.85. The trade was a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Andrew Stewart Plump also recently made the following trade(s):
- On Wednesday, August 19th, Andrew Plump sold 19,651 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $18.49, for a total transaction of $363,346.99.
- On Monday, August 10th, Andrew Plump sold 165,393 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total transaction of $2,828,220.30.
Takeda Pharmaceutical Stock Performance
Shares of TAK stock opened at $18.46 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The company's fifty day moving average price is $17.32 and its two-hundred day moving average price is $17.21. The firm has a market capitalization of $59.15 billion, a P/E ratio of 54.29 and a beta of -0.07. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.41 by $0.54. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The business had revenue of $7.50 billion for the quarter, compared to analyst estimates of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, research analysts anticipate that Takeda Pharmaceutical Co. will post 1.54 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Takeda Pharmaceutical
Several large investors have recently modified their holdings of the stock. Parkside Financial Bank & Trust grew its stake in Takeda Pharmaceutical by 192.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company's stock worth $40,000 after purchasing an additional 1,684 shares in the last quarter. SHP Wealth Management acquired a new stake in Takeda Pharmaceutical during the fourth quarter valued at approximately $42,000. Caitong International Asset Management Co. Ltd lifted its holdings in Takeda Pharmaceutical by 313.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company's stock worth $48,000 after buying an additional 2,328 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company's stock worth $55,000 after acquiring an additional 1,292 shares in the last quarter. Finally, Harbour Investments Inc. grew its position in shares of Takeda Pharmaceutical by 300.3% in the 4th quarter. Harbour Investments Inc. now owns 4,612 shares of the company's stock worth $72,000 after acquiring an additional 3,460 shares in the last quarter. Institutional investors own 9.17% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on TAK shares. Zacks Research upgraded Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a report on Wednesday. Wall Street Zen raised shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Takeda Pharmaceutical has a consensus rating of "Moderate Buy".
Check Out Our Latest Analysis on TAK
Takeda Pharmaceutical Company Profile
(
Get Free Report)
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
